T-Cell Lymphoma Forum 2013

 
 
 

 

Regimen can bridge to allo-SCT

Jen Smith Read Article
Published: 02/08/13

rapezzi_davide_MD_Credit_larryyoungphotos_230.jpg
Davide Rapezzi, MD
Credit: larryyoungphotos.com

Results of a small, single-center study suggest the effects of CHOP-alemtuzumab are age-dependent in patients with peripheral T-cell lymphoma (PTCL). The study included newly diagnosed patients who were set to receive CHOP-alemtuzumab, with or without additional high-dose therapy. A majority of patients aged 60 or younger achieved a response and went on to receive allogeneic stem cell transplant (allo-SCT). But most older patients did not derive any benefit from . . . [Read Article]

Pralatrexate falls short in ATL study

Jen Smith Read Article
Published: 02/06/13

horwitz_steven_md_Credit_larryyoungphotos.com_230.jpg
Steven Horwitz, MD
Credit: larryyoungphotos.com

Results of a small, retrospective study indicate pralatrexate does not perform as well in patients with adult T-cell leukemia/lymphoma (ATL) as it does in patients with other peripheral T-cell lymphomas (PTCLs). The drug elicited poorer response and survival rates in patients with relapsed or refractory ATL than those observed in a previous study of relapsed or refractory PTCL patients. Researchers also found evidence to suggest the risk of Stevens-Johnson Syndrome (SJS) may be higher in ATL patients. [Read Article]

Lennert lymphoma can stand alone, study suggests

Jen Smith Read Article
Published: 02/05/13

piccaluga_pier_paolo_Credit_larryyoungphotos.com_230.jpg
Pier Paolo Piccaluga, MD, PhD
Credit: larryyoungphotos.com

Lennert lymphoma may soon be regarded as an independent entity among T-cell lymphomas, according to a presenter at the 5th Annual T-cell Lymphoma Forum. Pier Paolo Piccaluga, MD, PhD, of the University of Bologna in Italy, and his colleagues found evidence to suggest that Lennert lymphoma is not simply a morphological variant of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS). The team identified 90 genes that were differentially expressed . . . [Read Article]

Romidepsin responses few but durable

Jen Smith Read Article
Published: 02/04/13

TCLF_2013_attendees_Credit_larryyoungphotos_220.jpg
Attendees at the 5th Annual
T-cell Lymphoma Forum
Credit: larryyoungphotos.com

Although most patients enrolled in a phase 2 study of romidepsin did not respond to the drug, those who did experienced durable responses and improved survival. The trial tested single-agent romidepsin in patients with relapsed or refractory peripheral T-cell lymphomas (PTCLs). The overall response rate was low, but the median duration of response was 28 months, with some patients maintaining a response for more than 48 months. And this translated to improvements in . . . [Read Article]

Mortality on the decline in ATL

Jen Smith Read Article
Published: 02/01/13

chihara_dai_MD_Credit_larryyoungphotos_230.jpg
Dai Chihara, MD
Credit: larryyoungphotos.com

New research points to a decreasing trend in mortality for Japanese patients with adult T-cell leukemia/lymphoma (ATL). A team of researchers assessed the mortality incidence in ATL patients in Japan between 1995 and 2009. The group found that, after an initial increase, the mortality rate has started to drop by about 3% each year. Dai Chihara, MD, of Aichi Cancer Center Research Institute in Nagoya, Japan, presented these data at the 5th Annual T-cell Lymphoma Forum. [Read Article]

How mogamulizumab stacks up in PTCL/CTCL

Jen Smith Read Article
Published: 01/31/13

Tobinai_Kensei_Credit_larryyoungphotos_230.jpg
Kensei Tobinai, MD, PhD
Credit: larryyoungphotos.com

Results of a phase 2 study suggest the anti-CCR4 antibody mogamulizumab (KW-0761) does not fare as well in other T-cell lymphomas as it does in adult T-cell leukemia/lymphoma (ATL). Investigators tested the drug in relapsed patients with peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL) and found the overall response rate was 35%. In a previous phase 2 study of patients with relapsed ATL, mogamulizumab elicited an overall response rate of 50%. [Read Article]

Protein associated with prognosis in PTCL-NOS

Jen Smith Read Article
Published: 01/30/13

niitsu_nozomi_Credit_larryyoungphotos.com_230.jpg
Nozomi Niitsu, MD, PhD
Credit: larryyoungphotos.com

Researchers say they have identified an important prognostic factor for peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS). The group found that expression of the protein nm23-H1 is associated with response to therapy, progression-free survival, and overall survival in PTCL-NOS. And, because it appears that nm23-H1 is produced in the lymphoma cells, the protein may be a viable target for therapy.  Nozomi Niitsu, MD, PhD, of Saitama Medical University in Hidaka, Japan, presented . . . [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}